1. Poller L., Roberts C., Ibrahim S., Keown M., Ageno W., van den Besselaar A.M.H.P. et al. Screening computer-assisted dosage programs for anticoagulation with warfarin and other vitamin K-antagonists: minimum safety requirements for individual programs. J. Thromb. Haemost. 2009; 7(10): 1736.
2. Njaastad A.M., Abildgaard U., Lassen J.F. Gains and losses of warfarin therapy as
3. performed in an anticoagulation clinic. J. Intern. Med. 2006; 259(3): 296-304.
4. Roehrig S., Straub A., Pohlmann J., Lampe T., Pernerstorfer J., Schlemmer K.H. et al. Discovery of the novel antithrombotic agent 5-Chloro-N-(?Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016; 37(38): 2893-962.
5. Lippi G., Favaloro E.J. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin. Chem. Lab. Med. 2015; 53(2): 185-97.